Literature DB >> 2464645

Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element.

A X Le1, E J Bernhard, M J Holterman, S Strub, P Parham, E Lacy, V H Engelhard.   

Abstract

Previous studies have indicated that the frequency of murine CTL precursors (CTLp) for human class I molecules is one to two orders of magnitude lower than that for murine class I alloantigens, and that this is due to species-specific structural differences between these molecules. Transgenic mice expressing the human class I MHC Ag HLA-A2.1 were used to examine changes in the frequency of class I HLA-specific precursors after T cell differentiation in an HLA-A2.1 positive environment. The HLA-A2.1 gene product was expressed at levels comparable to those of the endogenous H-2Db molecule in thymus, bone marrow, and spleen. By limiting dilution analysis, it was observed that the frequencies of CTLp in transgenic mice responding to the human alloantigens HLA-B7 or HLA-A2.2 were comparable to or lower than those in normal C57BL/6 mice, regardless of whether the Ag was presented on human or murine cells. Thus, expression of a human class I molecule in these animals did not result in an expansion of the number of CTLp specific for other human class I Ag. In addition, the frequency of HLA-A2.1-restricted, influenza specific CTLp was substantially lower than the frequency of H-2b restricted CTLp, indicating a poor utilization of HLA-A2.1 as a restricting element. Finally, the frequencies of CTLp for HLA-A2.1 expressed on syngeneic murine tumor cells were decreased significantly. Thus, expression of HLA-A2.1 in these animals appeared to induced tolerance to this Ag. Interestingly, however, these mice were not tolerant to the HLA-A2.1 molecule expressed on human cells. This indicates that the HLA-A2.1 associated epitopes expressed on murine and human cells differ and suggests that, under these circumstances, HLA-A2.1 acts as a restricting element for human nominal Ag. These results are discussed in the context of current models of T cell repertoire development.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464645

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

2.  CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa.

Authors:  Amale Laouar; Viraga Haridas; Dorothy Vargas; Xia Zhinan; David Chaplin; Rene A W van Lier; N Manjunath
Journal:  Nat Immunol       Date:  2005-06-05       Impact factor: 25.606

3.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

4.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Authors:  C Wei; R A Willis; B R Tilton; R J Looney; E M Lord; R K Barth; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  HLA antibody responses in HLA class I transgenic mice.

Authors:  T Tahara; S Y Yang; R Khan; S Abish; G J Hämmerling; U Hämmerling
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design.

Authors:  Daniela Weiskopf; Lauren E Yauch; Michael A Angelo; Daisy V John; Jason A Greenbaum; John Sidney; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Howard Grey; Bjoern Peters; Sujan Shresta; Alessandro Sette
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

7.  Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.

Authors:  Jing Yang; Yabing Cao; Sungyongl Hong; Haiyan Li; Jianfei Qian; Larry W Kwak; Qing Yi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.

Authors:  Jiafen Hu; Xuwen Peng; Lynn R Budgeon; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

9.  HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.

Authors:  Rachid Boucherma; Hédia Kridane-Miledi; Romain Bouziat; Michael Rasmussen; Tanja Gatard; Francina Langa-Vives; Brigitte Lemercier; Annick Lim; Marion Bérard; Lbachir Benmohamed; Søren Buus; Ronald Rooke; François A Lemonnier
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

10.  Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice.

Authors:  Michele P Marron; Robert T Graser; Harold D Chapman; David V Serreze
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.